Nafamostat is one of the serine protease inhibitors
COVID-19: Corona therapeutic drug candidate’Fusan’: Possibility of effect on mutant type
-Corona therapeutic drug candidate “Fusan”-
“Fusan”, a drug that is undergoing clinical research as a candidate for a new coronavirus drug
It turned out that “there was an experimental result that it may be effective against mutant viruses”.
Professor Inoue Research Team of the University of Tokyo:
Professor Inoue’s research team at the University of Tokyo has found that it may be effective against pancreatitis.
We have been conducting clinical research since last year.
Explain the administration effect with a graph:
The orange line is the conventional type,
Yellow is South African type,
Blue is Indian type.
The more to the right, the higher the concentration of fusan.
Any mutant virus
The higher the concentration of fusan, the more
As with the traditional type, infection is suppressed.
Fusan was effective against all strains.
Junichiro Inoue, Professor, The University of Tokyo:
If Fusan doesn’t work for Indian stocks
Only Indian stocks will go up the graph.
But all the variants are down together.
From this result, it is considered that the effect of Fusan is as effective as the conventional strain on the mutant strains that have appeared so far.
Aim for approval within the year:
National approval is required to make it a therapeutic drug for the new corona.
Professor Inoue says that he wants to proceed with clinical research and “aim for approval by the end of the year.”
-TV Asahi news site
https://news.tv-asahi.co.jp/news_society/articles/000218222.html